Pfizer announced positive findings from two phase 3 trial of the investigational antibiotic combination aztreonam-avibactam.
Infections are up in two regions: the Western Pacific by 10% and Africa by 3%.
At 24 months, the severity of health impairment declined, with 10.4% reporting mild, 3.9% moderate, and 1.9% severe impairment.
Infectious disease information from CIDRAP.
COVID-19 discussion & analysis on the latest developments by Dr. Osterholm and Chris Dall.
CIDRAP staff are frequently featured on other news sites. Please see our opinion pieces, commentaries, and other features.
Data on novel vaccine candidates in clinical or late preclinical development.
CIDRAP and COVID-19 podcast merchandise is available for purchase. Order t-shirts, mugs, socks, buttons, stickers, and more!
The Influenza Vaccines R&D Roadmap Initative
The Influenza Vaccines Roadmap provides a much-needed framework for organizing the efforts of existing influenza researchers while identifying a wide range of opportunities that will encourage new investigators to join the work.
[Turning new COVID-19 antibodies into approved drugs is] "going to take long-term investment. That is something we are missing.”
Study on masks vs N95 respirators for health workers spurs concerns
The findings suggest medical masks may offer similar protection as respirators against COVID-19, but experts say hold on.
Study says most long-COVID symptoms resolve by 1 year after mild cases, but experts not so sure
Many long-COVID patients have reported facing skepticism when seeking relief at their doctor's office.